US FDA delays approval of Regenerative (REGN.US) /Sanofi (SNY.US) dupixent for COPD

Regenerative Pharmaceuticals (REGN.US) and Sanofi (SNY.US) announced on Friday that the US FDA is delaying its decision to use its blockbuster drug dupixent (dupilumab) to treat chronic obstructive pulmonary disease (COPD).

Zhitong FinanceMay 31 21:49

FDA Extends Review Deadline For Regeneron/Sanofi's Dupixent For 'Smoker's Lungs' Disease

On Friday, the FDA extended the target action date of priority review of supplemental application seeking approval for Dupixent (dupilumab) as an add-on maintenance treatment in certain adult patients

BenzingaMay 31 21:23

Sanofi, Regeneron's Dupixent Receives Recommendation for Approval From European Medicines Agency Committee

The European Medicines Agency's Committee for Medicinal Products for Human Use has recommended the approval of dupilumab, known as Dupixent, in the European Union as an add-on maintenance treatment fo

MT NewswiresMay 31 19:32

Press Release: Sanofi Launches 2024 Global Employee Stock Purchase Plan

Sanofi launches 2024 global Employee Stock Purchase Plan Paris, May 31, 2024. Sanofi's global employee shareholder plan, Action 2024, opens on June 4, 2024, to around 80,000 employees in 56 countries. Now in its 10th

GlobeNewswireMay 31 18:00

Analysts Offer Insights on Healthcare Companies: Veeva Systems (VEEV), Gilead Sciences (GILD) and Sanofi (OtherSNYNF)

TipRanksMay 31 17:50

Express News | European Medicines Supervisory Authority recommends approval of Dupixen for the treatment of patients with chronic obstructive pulmonary disease

BreakingsMay 31 14:46